Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2022 May 28

PMID 35630534

Authors

Ruili Yin

YongSong Xu

Xin Wang

Longyan Yang

Dong Zhao

Affiliations

Soon will be listed here.

Abstract

In recent years, important changes have occurred in the field of diabetes treatment. The focus of the treatment of diabetic patients has shifted from the control of blood glucose itself to the overall management of risk factors, while adjusting blood glucose goals according to individualization. In addition, regulators need to approve new antidiabetic drugs which have been tested for cardiovascular safety. Thus, the newest class of drugs has been shown to reduce major adverse cardiovascular events, including sodium-glucose transporter 2 (SGLT2) and some glucagon like peptide 1 receptor (GLP1) analog. As such, they have a prominent place in the hyperglycemia treatment algorithms. In recent years, the role of DPP4 inhibitors (DPP4i) has been modified. DPP4i have a favorable safety profile and anti-inflammatory profile, do not cause hypoglycemia or weight gain, and do not require dose escalation. In addition, it can also be applied to some types of chronic kidney disease patients and elderly patients with diabetes. Overall, DPP4i, as a class of safe oral hypoglycemic agents, have a role in the management of diabetic patients, and there is extensive experience in their use.

Citing Articles

In Vitro and In Silico Antidiabetic Efficacy of Solanum lasiocarpum Dunal Fruit Extract.

Zhao J, Najm A, Mahmood I, Ming Z, Dutta P, Talib W PLoS One. 2025; 20(3):e0312600.

PMID: 40063647 PMC: 11892833. DOI: 10.1371/journal.pone.0312600.

Impact of Dipeptidyl Peptidase-4 Inhibitors on Aminotransferases Levels in Patients with Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trial.

Ma G, Zhang S, Yu B Curr Ther Res Clin Exp. 2025; 102():100768.

PMID: 39831144 PMC: 11741081. DOI: 10.1016/j.curtheres.2024.100768.

Multi Targeted Activity of Cocculus hirsutus through Modulation of DPP-IV and PTP-1B Leading to Enhancement of Glucose Uptake and Attenuation of Lipid Accumulation.

Bhuvaneswari D, Riitvek B, Lakshmi B Appl Biochem Biotechnol. 2025; .

PMID: 39760988 DOI: 10.1007/s12010-024-05142-8.

Clinical Profile, Comorbidities and Therapies in Type 2 Diabetes Patients on Sitagliptin-Based Therapy in Indian Outpatient Setting.

Bhat K, Singh K, Maddukuri H, Routray S, Sharma S, Sharma S Cureus. 2024; 16(11):e74820.

PMID: 39737272 PMC: 11684534. DOI: 10.7759/cureus.74820.

Predicting hypoglycemia in elderly inpatients with type 2 diabetes: the ADOCHBIU model.

Zhang R, Liu Y, Sun C, Wu Q, Guo H, Wang G Front Endocrinol (Lausanne). 2024; 15:1366184.

PMID: 39610841 PMC: 11602273. DOI: 10.3389/fendo.2024.1366184.

References

Huang J, Jia Y, Sun S, Meng L . Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. BMC Pharmacol Toxicol. 2020; 21(1):68. PMC: 7493367. DOI: 10.1186/s40360-020-00447-w. View

Wronkowitz N, Gorgens S, Romacho T, Villalobos L, Sanchez-Ferrer C, Peiro C . Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2. Biochim Biophys Acta. 2014; 1842(9):1613-21. DOI: 10.1016/j.bbadis.2014.06.004. View

He Y, Wang Y, Bullock J, Deacon C, Holst J, Dunning B . Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol. 2007; 47(5):633-41. DOI: 10.1177/0091270006299137. View

Boulton D . Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor. Clin Pharmacokinet. 2016; 56(1):11-24. DOI: 10.1007/s40262-016-0421-4. View

Scheen A . Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010; 12(8):648-58. DOI: 10.1111/j.1463-1326.2010.01212.x. View

Molina-Vega M, Munoz-Garach A, Fernandez-Garcia J, Tinahones F . The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies. Expert Opin Drug Saf. 2018; 17(8):815-824. DOI: 10.1080/14740338.2018.1497158. View

Lascar N, Brown J, Pattison H, Barnett A, Bailey C, Bellary S . Type 2 diabetes in adolescents and young adults. Lancet Diabetes Endocrinol. 2017; 6(1):69-80. DOI: 10.1016/S2213-8587(17)30186-9. View

Graefe-Mody U, Retlich S, Friedrich C . Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet. 2012; 51(7):411-27. DOI: 10.2165/11630900-000000000-00000. View

Biessels G, Verhagen C, Janssen J, van den Berg E, Zinman B, Rosenstock J . Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial. Diabetes Care. 2019; 42(10):1930-1938. DOI: 10.2337/dc19-0783. View

10.

Ahren B, Foley J, Bosi E . Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab. 2011; 13(3):193-203. DOI: 10.1111/j.1463-1326.2010.01321.x. View

11.

Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K, Nakahori Y . Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol. 2008; 200(1):53-61. DOI: 10.1677/JOE-08-0424. View

12.

Mannucci E, Nreu B, Montereggi C, Ragghianti B, Gallo M, Giaccari A . Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2021; 31(10):2745-2755. DOI: 10.1016/j.numecd.2021.06.002. View

13.

Varin E, Mulvihill E, Beaudry J, Pujadas G, Fuchs S, Tanti J . Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition. Cell Metab. 2018; 29(2):320-334.e5. DOI: 10.1016/j.cmet.2018.10.001. View

14.

Shimizu S, Hosooka T, Matsuda T, Asahara S, Koyanagi-Kimura M, Kanno A . DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice. J Mol Endocrinol. 2012; 49(2):125-35. DOI: 10.1530/JME-12-0039. View

15.

Thornberry N, Weber A . Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem. 2007; 7(6):557-68. DOI: 10.2174/156802607780091028. View

16.

Han C, Lee W, Hsu C, Huang Y, Lin C, Tsai C . DPP4 reduces proinflammatory cytokine production in human rheumatoid arthritis synovial fibroblasts. J Cell Physiol. 2021; 236(12):8060-8069. DOI: 10.1002/jcp.30494. View

17.

Zhou S, Cui W, Kong L, Yang X . Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice. Curr Med Sci. 2022; 42(3):513-519. DOI: 10.1007/s11596-022-2573-9. View

18.

Sharma A, Paliwal G, Upadhyay N, Tiwari A . Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment. J Diabetes Metab Disord. 2015; 14:15. PMC: 4607261. DOI: 10.1186/s40200-015-0143-4. View

19.

Khalil R, Shata A, Abd El-Kader E, Sharaf H, Abdo W, Amin N . Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38α, and NF-κB signaling. Toxicol Appl Pharmacol. 2020; 407:115246. DOI: 10.1016/j.taap.2020.115246. View

20.

Yang M, Chen X, Chen X, Liu H, Zhang Z . Protective effect of vildagliptin on myocardial injury in septic rats by regulating TLR-4/NF-κB pathway. Minerva Med. 2019; 112(4):522-524. DOI: 10.23736/S0026-4806.19.06242-6. View